CinFina Pharma, a CinRx portfolio company focused on obesity treatments, has released promising interim data from a Phase 1 single ascending dose (SAD) study of CIN-110 and final data from a multiple ascending dose (MAD) study of CIN-109. Both treatments demonstrated tolerability and significant weight loss.
CIN-110, a long-acting PYY3-36 analog, is designed to minimize gastrointestinal side effects often associated with subcutaneous administration. Interim data from the double-blind Phase 1 SAD study indicated the treatment was well-tolerated in obese participants. It showed encouraging reductions in caloric intake and subsequent weight loss compared to a placebo after a single dose. Within one week, food intake decreased by up to 28%, leading to a weight loss of up to 1.8%. The study involved 24 obese participants with an average baseline weight of approximately 102 kg and a body mass index (BMI) of approximately 34 kg/m2. CIN-110 is engineered to gradually increase and sustain drug exposure, mitigating common gastrointestinal side effects. Three mild nausea cases were reported, typically resolving within a day. Pharmacokinetic data revealed a gradual increase in CIN-110 levels, peaking within two to three days and sustaining with a roughly 14-day half-life. No participants withdrew due to adverse events, and all side effects were mild or moderate, with moderate events unrelated to the digestive system.
CIN-109, a long-acting, first-in-class GDF-15 analog, aims to reduce appetite, maintain energy expenditure, and promote weight loss while preserving lean body mass. Results from the Phase 1 MAD study showed it was well-tolerated and resulted in substantial weight loss in obese participants. In this randomized, double-blind, placebo-controlled study, participants received weekly doses of CIN-109 (5 mg, 10 mg, 15 mg, 20 mg, or 40 mg) or bi-weekly doses (20 mg, 40 mg, or 60 mg). The weekly group received treatment for four weeks, while the bi-weekly group received treatment for eight weeks. Participants had an average weight of approximately 100 kg and a BMI of approximately 35 kg/m2. Participants experienced reduced food intake, with dose-dependent decreases of up to 50%, and resulting weight loss of up to 3.7% within one to two months. Bi-weekly dosing proved to be better tolerated, and the majority of weight loss was attributed to fat mass reduction. No serious treatment-related side effects were observed.
CIN-110 is a long-acting PYY3-36 analog designed to minimize nausea and vomiting often associated with other PYY molecules while promoting weight loss. It is currently undergoing clinical trials to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity.
CIN-109 is a Phase 2 ready, first-in-class GDF-15 analog for obesity treatment. It has successfully completed a randomized, double-blind, placebo-controlled MAD study assessing its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity when administered subcutaneously.
CinFina Pharma, part of the CinRx portfolio, is dedicated to expanding obesity treatment options. It is developing a pipeline of therapeutic candidates intended to be safe, tolerable, and long-lasting to support weight loss and overall health improvement. CinFina’s four therapeutic candidates are naturally occurring, engineered peptides designed to regulate insulin secretion and satiety signals.
CinRx Pharma employs a unique hub-and-spoke business model to advance a diverse portfolio of medicines through clinical development. This approach combines financing with efficient therapeutic candidate progression, managed by CinRx’s central infrastructure and operations team. CinRx focuses on areas of high unmet medical need, including metabolic, gastrointestinal, and oncological conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
